NANOPHARMACEUTICALS, LLC
BG-P-TAT (NP855), a dual-targeting therapeutic molecule combining a norepinephrine transporter ligand and integrin αvβ3 antagonist for neuroblastoma treatment
- Sector
- Biotech
- Headquarters
- Troy, NY
- Founded
- 2013
- Latest Form D
- $623K, Feb 2025
- Total capital
- $8.2M
- Federal grants
- $1.7M
- 2 awards · 2024–2025
- Rank in peer group#132 of 326
- Private capital raised
- $6.6M
- 4 Form D · last Feb 2025
- 21 months since last filing
- Federal contracts
- None on recordNo federal contract awards found.
- Granted patents
- 15
- 7 pending · first 2015
- Rank in peer group#14 of 326
Capital timeline
Latest events
- Federal grantHealth and Human S · Phase II · NP855 for Targeting Thyrointegrin αvβ3 receptors and Norepinephrine Transporter in Neuroblastoma Management$869K
- Private capital raisedForm D · SEC · 4th filing$623K
- Federal grantHealth and Human S · Phase II · NP855 for Targeting Thyrointegrin αvβ3 receptors and Norepinephrine Transporter in Neuroblastoma Management$792K
- Private capital raisedForm D · SEC · 3rd filing$1.3M
- Private capital raisedForm D · SEC · 2nd filing$2M
- Private capital raisedForm D · SEC · 1st filing$2.6M
Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.
Standing among 326 peers
Line = medianBiotech · Molecule
- Federal grants#132 · top 40%
- Granted patents#14 · top 4%
Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.
Founders and team
Researcher links verified by same-company patents and grants- Shaker A. MousaResearcherExecutive Officer, DirectorLinked by 14 patents
- Paul J. DavisResearcherExecutive Officer, DirectorLinked by $1.7M in grants as PI
- Carl WalkeyExecutive OfficerNamed in SEC Form D filings
- Eliza McKinneyExecutive OfficerNamed in SEC Form D filings
- Eliza A. ParkerExecutive OfficerNamed in SEC Form D filings
- James A. GozzoExecutive Officer, DirectorNamed in SEC Form D filings
Show all 8 people
- Michael J. RosenthalExecutive Officer, DirectorNamed in SEC Form D filings
- T. Gregory DeweyDirectorNamed in SEC Form D filings
What it has protected
USPTO · 15 granted of 22- GrantedPolymer Conjugated Thyrointegrin AntagonistsUSPTOUS 11,723,888
- GrantedComposition And Method For Dual Targeting In Treatment Of Neuroendocrine TumorsUSPTOUS 11,351,137
- GrantedComposition Of Scalable Thyrointegrin Antagonists With Improved Retention In TumorsUSPTOUS 11,186,551
Show all 22 patent records
- Polymer Conjugated Thyrointegrin AntagonistsAug 15, 2023 · US 11,723,888Granted
- Composition And Method For Dual Targeting In Treatment Of Neuroendocrine TumorsJun 7, 2022 · US 11,351,137Granted
- Composition Of Scalable Thyrointegrin Antagonists With Improved Retention In TumorsNov 30, 2021 · US 11,186,551Granted
- Composition And Method For Dual Targeting In Treatment Of Neuroendocrine TumorsAug 3, 2021 · US 11,077,082Granted
- Composition Of Scalable Thyrointegrin Antagonists With Improved Blood Brain Barrier Penetration And Retention Into Brain TumorsMar 30, 2021 · US 10,961,204Granted
- Non-cleavable Polymer Conjugated With Alpha V Beta 3 Integrin Thyroid AntagonistsJun 30, 2020 · US 10,695,436Granted
- Composition And Method For Dual Targeting In Treatment Of Neuroendocrine TumorsJun 25, 2019 · US 10,328,043Granted
- Non-cleavable Polymer Conjugated With Alpha V Beta 3 Integrin Thyroid AntagonistsFeb 12, 2019 · US 10,201,616Granted
- Method And Composition Of Thyroid Hormone Analogoues And Nanoformulations Thereof For Treating Inflammatory DisordersNov 20, 2018 · US 10,130,686Granted
- Methods For Screening Patients For Resistance To Angioinhibition, Treatment And Prophylaxis ThereofAug 28, 2018 · US 10,060,934Granted
- Nanoparticle And Polymer Formulations For Thyroid Hormone Analogs, Antagonists, And Formulations And Uses ThereofDec 12, 2017 · US 9,839,614Granted
- Nanoparticle And Polymer Formulations For Thyroid Hormone Analogs, Antagonists, And Formulations ThereofSep 5, 2017 · US 9,750,709Granted
- Nanoparticle And Polymer Formulations For Thyroid Hormone Analogs, Antagonists, And Formulations ThereofFeb 28, 2017 · US 9,579,300Granted
- Method And Composition Of Thyroid Hormone Analogues And Nanoformulations Thereof For Treating Anti-inflammatory DisordersNov 22, 2016 · US 9,498,536Granted
- Nanoparticle And Polymer Formulations For Thyroid Hormone Analogs, Antagonists, And Formulations And Uses ThereofDec 29, 2015 · US 9,220,788Granted
- Small Molecule Ligands of the Integrin RGD Recognition Site and Methods of UseJun 24, 2010 · Application 12644493Pending
- Methods For Screening Patients For Resistance To Angioinhibition, Treatment And Prophylaxis ThereofApplication PCTUS2014066154Pending
- Non-cleavable Polymer Conjugated With AVB3 Integrin Thyroid AntagonistsApplication PCTUS2017036396Pending
- Composition And Method For Dual Targeting In Treatment Of Neuroendocrine TumorsApplication PCTUS2019025489Pending
- Composition Of Scalable Thyrointegrin Antagonists With Improved Blood Brain Barrier Penetration And Retention In Brain TumorsApplication PCTUS2021024294Pending
- Composition And Method For Dual Targeting In Treatment Of Neuroendocrine TumorsApplication PCTUS2022031876Pending
- Polymer Conjugated Thyrointegrin AntagonistsApplication PCTUS2022051900Pending
Related companies, and why
- Salve Therapeutics, Inc.Similar federal contract value in Biotech · null in contracts
- RHEUMAGEN, INC.Similar federal contract value in Biotech · null in contracts
- BioLineRx Ltd.Similar federal contract value in Biotech · null in contracts
- Nerio TherapeuticsSimilar federal contract value in Biotech · null in contracts
- Zafrens Inc.Similar federal contract value in Biotech · null in contracts
- Invenra Inc.Similar federal contract value in Biotech · null in contracts
Regulatory activity · Biotech
- New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
- Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
- Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
- Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
- Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
- Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration
Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.
Sources
Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.
How to read this page
Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.
Data freshness
SEC Form D filings through . SBIR and STTR awards through .